KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Research & Development (2016 - 2025)

Historic Research & Development for Neogenomics (NEO) over the last 15 years, with Q4 2025 value amounting to $9.2 million.

  • Neogenomics' Research & Development rose 1518.38% to $9.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $37.1 million, marking a year-over-year increase of 1899.29%. This contributed to the annual value of $37.1 million for FY2025, which is 1899.29% up from last year.
  • As of Q4 2025, Neogenomics' Research & Development stood at $9.2 million, which was up 1518.38% from $8.7 million recorded in Q3 2025.
  • Neogenomics' Research & Development's 5-year high stood at $10.2 million during Q1 2025, with a 5-year trough of $2.5 million in Q1 2021.
  • For the 5-year period, Neogenomics' Research & Development averaged around $7.4 million, with its median value being $7.7 million (2024).
  • In the last 5 years, Neogenomics' Research & Development soared by 30538.1% in 2021 and then plummeted by 2772.16% in 2023.
  • Over the past 5 years, Neogenomics' Research & Development (Quarter) stood at $8.5 million in 2021, then fell by 21.59% to $6.7 million in 2022, then grew by 6.77% to $7.1 million in 2023, then increased by 11.81% to $8.0 million in 2024, then grew by 15.18% to $9.2 million in 2025.
  • Its Research & Development was $9.2 million in Q4 2025, compared to $8.7 million in Q3 2025 and $9.0 million in Q2 2025.